Moreover, using blocking antibodies against the ectonucleotidases responsible for ATP degradation, namely CD73 (or NT5E) and CD39 (or ENTPD1), antitumor immunity was boosted through the P2RX7/NLRP3 pathway, and tumor growth was inhibited in mouse models of melanoma, fibrosarcoma, colon and prostate tumors [108,109]. The gene discussed is ENTPD1; the disease is prostate neoplasm.